| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pediatrics, Division of Endocrinology, Sophia Children’s Hospital/Erasmus Medical Center (Y.v.P., A.H.-K.), 3015 GJ Rotterdam, The Netherlands; Department of Epidemiology and Biostatistics, Erasmus Medical Center (P.M.), 3015 GJ Rotterdam, The Netherlands; Academic Hospital of Free University (M.H.), 1081 HV Amsterdam, The Netherlands; Wilhelmina Children’s Hospital (M.J.), 3584 EA Utrecht, The Netherlands; and Juliana Children’s Hospital (M.R.), 2566 MJ The Hague, The Netherlands
Address all correspondence and requests for reprints to: A. C. S. Hokken-Koelega, M.D., Department of Pediatrics, Division of Endocrinology, Sophia Children’s Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands.
The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial. Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m2·d (
0.033 or 0.067 mg/kg·d, respectively). The mean (±SD) birth length was -3.6 (1.4), the age at the start of the study was 8.1 (1.9) yr, and the height SD score (SDS) at the start of the study -3.0 (0.7). Seventeen of the 54 children were partially GH deficient (stimulated GH peak, 10–20 mU/liter). Fifteen non-GH-treated, non-GH-deficient, short children born SGA, with similar inclusion criteria, served as controls [mean (±SD) birth length, -3.3 (1.2); age at start, 7.8 (1.7) yr; height SDS at start, -2.6 (0.5)]. GH treatment resulted in an AH above -2 SDS in 85% of the children after a mean (±SD) GH treatment period of 7.8 (1.7) yr. The mean (SD) AH SDS was -1.1 (0.7) for group A and -0.9 (0.8) for group B, resulting from a mean (±SD) gain in height SDS of 1.8 (0.7) for group A and 2.1 (0.8) for group B. No significant differences between groups A and B were found for AH SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.2, 0.6; P > 0.2) and gain in height SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.1, 0.7; P > 0.1). When corrected for target height, the mean corrected AH SDS was -0.2 (0.8) for group A and -0.4 (0.9) for group B. The mean (±SD) AH SDS of the control group [-2.3 (0.7)] was significantly lower than that of the GH-treated group (P < 0.001). Multiple regression analysis indicated the following predictive variables for AH SDS: target height SDS, height SDS, and chronological age minus bone age (years) at the start of the study. GH dose had no significant effect. In conclusion, long-term continuous GH treatment in short children born SGA without signs of persistent catch-up growth leads to a normalization of AH, even with a GH dose of 3 IU/m2·d (0.033 mg/kg·d).
This work was supported by Novo Nordisk A/S (Bagsvaerd, Denmark).
Abbreviations: AH, Adult height; ATT, arginine tolerance test; BA, bone age; BMI, body mass index; CA, chronological age; CI, confidence interval; GHD, GH deficiency; HV, height velocity; PI, prediction interval; SDS, SD score; SGA, small for gestational age; TH, target height.
This article has been cited by other articles:
 |
|
 |
|
  L. Audi, A. Carrascosa, C. Esteban, M. Fernandez-Cancio, P. Andaluz, D. Yeste, R. Espadero, M. L. Granada, H. Wollmann, L. Fryklund, et al. The exon 3-deleted/full-length Growth Hormone Receptor Polymorphism Does Not Influence the Effect of Puberty or Growth Hormone Therapy on Glucose Homeostasis in Short Non-Growth Hormone-Deficient Small-for-Gestational-Age Children: Results from a Two-Year Controlled Prospective Study J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2709 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Rotteveel, M M van Weissenbruch, and H A Delemarre-Van de Waal Decreased insulin sensitivity in small for gestational age males treated with GH and preterm untreated males: a study in young adults. Eur. J. Endocrinol., June 1, 2008; 158(6): 899 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. J. de Ridder, T. Stijnen, and A. C. S. Hokken-Koelega Prediction Model for Adult Height of Small for Gestational Age Children at the Start of Growth Hormone Treatment J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Carrascosa, L. Audi, C. Esteban, M. Fernandez-Cancio, P. Andaluz, M. Gussinye, M. Clemente, D. Yeste, and M. A. Albisu Growth Hormone (GH) Dose, But Not Exon 3-Deleted/Full-Length GH Receptor Polymorphism Genotypes, Influences Growth Response to Two-Year GH Therapy in Short Small-for-Gestational-Age Children J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. N. Bannink, J. van Doorn, P. G. H. Mulder, and A. C. S. Hokken-Koelega Free/Dissociable Insulin-Like Growth Factor (IGF)-I, Not Total IGF-I, Correlates with Growth Response during Growth Hormone Treatment in Children Born Small for Gestational Age J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2992 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Argente, R. Gracia, L. Ibanez, A. Oliver, E. Borrajo, A. Vela, J. P. Lopez-Siguero, M. L. Moreno, F. Rodriguez-Hierro, and on behalf of the Spanish SGA Working Group Improvement in Growth after Two Years of Growth Hormone Therapy in Very Young Children Born Small for Gestational Age and without Spontaneous Catch-Up Growth: Results of a Multicenter, Controlled, Randomized, Open Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3095 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Hardin, S. F. Kemp, and D. B. Allen Twenty Years of Recombinant Human Growth Hormone in Children: Relevance to Pediatric Care Providers Clinical Pediatrics, May 1, 2007; 46(4): 279 - 286. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Willemsen, M. van Dijk, Y. B. de Rijke, A. W. van Toorenenbergen, P. G. Mulder, and A. C. Hokken-Koelega Effect of Growth Hormone Therapy on Serum Adiponectin and Resistin Levels in Short, Small-for-Gestational-Age Children and Associations with Cardiovascular Risk Parameters J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Dijk, E. M. N. Bannink, Y. K. van Pareren, P. G. H. Mulder, and A. C. S. Hokken-Koelega Risk Factors for Diabetes Mellitus Type 2 and Metabolic Syndrome Are Comparable for Previously Growth Hormone-Treated Young Adults Born Small for Gestational Age (SGA) and Untreated Short SGA Controls J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 160 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Carrascosa, C. Esteban, R. Espadero, M. Fernandez-Cancio, P. Andaluz, M. Clemente, L. Audi, H. Wollmann, L. Fryklund, L. Parodi, et al. The d3/fl-Growth Hormone (GH) Receptor Polymorphism Does Not Influence the Effect of GH Treatment (66 {micro}g/kg per Day) or the Spontaneous Growth in Short Non-GH-Deficient Small-for-Gestational-Age Children: Results from a Two-Year Controlled Prospective Study in 170 Spanish Patients J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3281 - 3286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Dijk, P. Mulder, M. Houdijk, J. Mulder, K. Noordam, R. J. Odink, C. Rongen-Westerlaken, P. Voorhoeve, J. Waelkens, J. Stokvis-Brantsma, et al. High Serum Levels of Growth Hormone (GH) and Insulin-Like Growth Factor-I (IGF-I) during High-Dose GH Treatment in Short Children Born Small for Gestational Age J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1390 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. O. Ramirez-Yanez, J. R. Smid, W. G. Young, and M. J. Waters Influence of growth hormone on the craniofacial complex of transgenic mice Eur J Orthod, October 1, 2005; 27(5): 494 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rosilio, J.-C. Carel, E. Ecosse, J.-L. Chaussainon, and on behalf of the 0908 Lilly Study Group Adult height of prepubertal short children born small for gestational age treated with GH Eur. J. Endocrinol., June 1, 2005; 152(6): 835 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bridges New indications for growth hormone Arch. Dis. Child. Ed. Pract., June 1, 2005; 90(1): ep7 - ep9. [Full Text] [PDF]
|
|
|
|
 |
|
 F. de Zegher and A. Hokken-Koelega Growth Hormone Therapy for Children Born Small for Gestational Age: Height Gain Is Less Dose Dependent Over the Long Term Than Over the Short Term Pediatrics, April 1, 2005; 115(4): e458 - e462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P E Clayton, R C Cuneo, A Juul, J P Monson, S M Shalet, and M Tauber Consensus statement on the management of the GH-treated adolescent in the transition to adult care Eur. J. Endocrinol., February 1, 2005; 152(2): 165 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Brodsky and H. Christou Current Concepts in Intrauterine Growth Restriction J Intensive Care Med, November 1, 2004; 19(6): 307 - 319. [Abstract] [PDF]
|
|
|
|
|
|
Y. K. van Pareren, H. J. Duivenvoorden, F. S. M. Slijper, H. M. Koot, and A. C. S. Hokken-Koelega Intelligence and Psychosocial Functioning during Long-Term Growth Hormone Therapy in Children Born Small for Gestational Age J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5295 - 5302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L B Johnston and M O Savage Should recombinant human growth hormone therapy be used in short small for gestational age children? Arch. Dis. Child., August 1, 2004; 89(8): 740 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. H. Boonstra, P. G. H. Mulder, F. H. de Jong, and A. C. S. Hokken-Koelega Serum Dehydroepiandrosterone Sulfate Levels and Pubarche in Short Children Born Small for Gestational Age before and during Growth Hormone Treatment J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 712 - 717. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
